Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing Selective BRAF Inhibition
Authors:
- Uwe HillenUHUwe Hillen
- Elisabeth LivingstoneELElisabeth Livingstone
- Mario E. LacoutureMLMario E. Lacouture
- Klaus BusamKBKlaus Busam
- Richard D. CarvajalRCRichard D. Carvajal
- Friederike EgbertsFEFriederike Egberts
- Axel HauschildAHAxel Hauschild
- Mohammed Kashani-SabetMKMohammed Kashani-Sabet
- Simone M. GoldingerSGSimone M. Goldinger
- Reinhard DummerRDReinhard Dummer
- Georgina V. LongGLGeorgina V. Long
- 1 July 2012
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 30 (19) , 2375-2383
Abstract
Purpose: Selective inhibition of mutant BRAF by using class I RAF inhibitors in patients with metastatic melanoma has resulted in impressive clinical activity. However, there is also evidence that RAF inhibitors might induce carcinogenesis or promote tumor progression via stimulation of MAPK signaling in RAF wild-type cells. We analyzed melanocytic lesions arising under class I RAF inhibitor treatment for dignity, specific genetic mutations, or expression of signal transduction molecules. Patients and Methods: In all, 22 cutaneous melanocytic lesions that had either developed or considerably changed in morphology in 19 patients undergoing treatment with selective BRAF inhibitors for BRAF-mutant metastatic melanoma at seven international melanoma centers within clinical trials in 2010 and 2011 were analyzed for mutations in BRAF and NRAS genes and immunohistologically assessed for expression of various signal transduction molecules in comparison with 22 common nevi of 21 patients with no history of BRAF inhibitor treatment. Results: Twelve newly detected primary melanomas were confirmed in 11 patients within 27 weeks of selective BRAF blockade. In addition, 10 nevi developed of which nine were dysplastic. All melanocytic lesions were BRAF wild type. Explorations revealed that expression of cyclin D1 and pAKT was increased in newly developed primary melanomas compared with nevi (P = .01 and P = .03, respectively). There was no NRAS mutation in common nevi, but BRAF mutations were frequent. Conclusion: Malignant melanocytic tumors might develop with increased frequency in patients treated with selective BRAF inhibitors supporting a mechanism of BRAF therapy–induced growth and tumorigenesis. Careful surveillance of melanocytic lesions in patients receiving class I RAF inhibitors seems warranted.Keywords
This publication has 35 references indexed in Scilit:
- RAS Mutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF InhibitorsJournal of Clinical Oncology, 2012
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic MelanomaNew England Journal of Medicine, 2011
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- BRAF targeted therapy changes the treatment paradigm in melanomaNature Reviews Clinical Oncology, 2011
- Inhibition of Mutated, Activated BRAF in Metastatic MelanomaNew England Journal of Medicine, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- BRAF, a target in melanomaCancer, 2010
- Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors.Journal of Clinical Oncology, 2010
- Inhibitors that activateNature, 2010
- Final Version of 2009 AJCC Melanoma Staging and ClassificationJournal of Clinical Oncology, 2009